Skip to main content

Table 1 Patient demographic and laboratory findings

From: The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients

Variables

All patients

Patients with AOD

Patients without AOD

P

n (%)

159

79 (49.6%)

80 (50.4%)

 

Age (years)

52.02 ± 12.1

54.71 ± 12.0

49.36 ± 11.5

0.005*

Gender

   

0.115

Female, n (%)

113 (71.1)

61 (77.2)

52 (65)

 

Male, n (%)

46 (28.9)

18 (22.8)

28 (35)

 

BMI (kg/m2)

29.55 ± 4.7

30.04 ± 4.7

29.05 ± 4.6

0.195

Duration of HT (years)

3.74 (4)

5 (3)

2.5 (4)

0.037*

Antihypertensive drugs

    

Class (n,%)

    

RAS blocker

86 (54.1)

45 (57.0)

41 (51.2)

0.470

Beta blocker

28 (17.6)

17 (21.5)

11 (13.8)

0.198

CCB

63 (39.6)

35 (44.3)

28 (35.0)

0.230

Diuretic

54 (34)

26 (33.8)

28 (36.8)

0.691

CIMT (mm)

0.75 ± 0.17

0.80 ± 0.2

0.68 ± 0.1

0.001*

LVMI (g/m2)

90.05 ± 21.1

100.57 ± 21.1

78.64 ± 13.9

0.001*

Microalbuminuria (mg/d)

10 (15,8)

19.32 (41,7)

7.17 (6,9)

0.001*

Proteinuria (mg/d)

94.98 (70.4)

111.25 (114.8)

84.25 (59.1)

0.001*

Retinopathy (n,%)

   

0.002*

None

91 (57.2)

39 (49.4)

52 (65.0)

 

Grade I

28 (17.6)

13 (16.5)

15 (24.6)

 

Grade II

28 (17.6)

15 (19.0)

13 (21.3)

 

Grade III

12 (7.5)

12 (15.2)

-

 

sTWEAK (pg/mL)

961.12 (560.9)

858.4 (365.2)

1151.58 (598.4)

0.001*

IL-17A (pg/mL)

2.1 (0,9)

2.34 (0,9)

1.80 (0,7)

0.001*

24-h SBP (mmHg)

124.31 ± 14.7

129.53 ± 16.8

119.16 ± 9.9

0.001*

24-h DBP (mmHg)

77.83 ± 9.8

79.53 ± 11.8

76.15 ± 6.9

0.029*

  1. Numeric parameters are shown as mean ± SD and median (interquartile range).
  2. Categorical parameters are shown as n (%).
  3. *Denotes a significant difference between the groups (P < 0.05).